Jaeb Center for Health Research, Tampa, Florida, USA.
Dexcom, Inc., San Diego, California, USA.
Diabetes Technol Ther. 2021 Mar;23(3):230-233. doi: 10.1089/dia.2020.0471. Epub 2020 Oct 20.
The DIAMOND study demonstrated that real-time continuous glucose monitors (rtCGMs) improve glycemia for adults with type 1 diabetes using multiple daily injections. This analysis explores the relationship between baseline time in range (TIR) and improvement in TIR using rtCGMs or self-monitoring of blood glucose (SMBG). Baseline TIR was divided into three categories: <40% (9.6 h per day), <50% (12 h per day), and <60% (14.4 h per day). Compared with SMBG, use of rtCGMs increased mean TIR by an additional 16 min per day for participants with a baseline TIR <40%, 77 min per day for baseline TIR <50%, and 88 min per day for baseline TIR <60%. A greater percentage of participants increased TIR by >4 h per day using rtCGMs within the three baseline TIR groups. For participants with a baseline TIR <50%, 29% of rtCGM users improved their TIR by >4 h per day compared with no SMBG users ( < 0.001). Similar trends were found for improvement in mean glucose and time spent in hyper- and hypoglycemic ranges.
DIAMOND 研究表明，实时连续血糖监测仪（rtCGM）可改善接受多次每日注射治疗的 1 型糖尿病成人的血糖水平。本分析探讨了使用 rtCGM 或自我血糖监测（SMBG）时，基线时间在目标范围内（TIR）与 TIR 改善之间的关系。基线 TIR 分为三个类别：<40%（每天 9.6 小时）、<50%（每天 12 小时）和<60%（每天 14.4 小时）。与 SMBG 相比，对于基线 TIR <40%的参与者，使用 rtCGM 可使平均 TIR 每天额外增加 16 分钟，基线 TIR <50%的参与者每天增加 77 分钟，基线 TIR <60%的参与者每天增加 88 分钟。在三个基线 TIR 组中，更多的参与者使用 rtCGM 使 TIR 增加超过 4 小时/天。对于基线 TIR <50%的参与者，与没有 SMBG 用户相比，29%的 rtCGM 用户 TIR 增加超过 4 小时/天（ < 0.001）。在改善平均血糖和高血糖及低血糖时间方面也发现了类似的趋势。
